Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children
NCT05545384Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azathioprine and rituximab in Acute demyelinating syndrome (ADS) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Annualized Relapse Rate at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
azathioprinerituximab
03
Conditions
Acute demyelinating syndrome (ADS)myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on NCT05545384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545384.